Takhzyro 150 MG
Ended Awarded
- Contract number
- 36C24526N0303
- Awardee
-
Takeda Pharmaceuticals America, Inc. UEI DDEVYUAXJ624
- Awarding agency
-
Veterans Integrated Service Network 5
Veterans Health Administration, Department of Veterans Affairs
- Obligated
- $38,098
Award facts
- Contract value 100% obligated
- $38,097.52 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Brooks, KY 40109, USA
Award details come from SAM.gov/FPDS.
About this award
On February 5, 2026, the Department of Veterans Affairs, Veterans Integrated Service Network 5, awarded a delivery order valued at $38,097.52 to Takeda Pharmaceuticals America Inc. for the supply of TAKHZYRO 150 MG, a specialized pharmaceutical treatment for rare genetic disorders. This firm fixed-price delivery order is issued under a parent Blanket Purchase Agreement established on the General Services Administration Pharmaceuticals and Drugs Schedule (FSS-61-IB), which provides streamlined procurement capabilities for advanced biopharmaceutical products supporting federal healthcare delivery. The contract carries no set-aside designation, reflecting the specialized and often single-source nature of this critical medication. Performance is scheduled for completion by February 10, 2026, at the contractor's facility in Brooks, Kentucky.
Takeda Pharmaceuticals America Inc., a subsidiary of Japan-based Takeda Pharmaceutical Company Limited, serves as the prime contractor and is a critical supplier of specialized pharmaceutical products to multiple federal agencies. The company holds a comprehensive single-award BPA valued at $131.04 million with the Department of Veterans Affairs National Acquisition Center through July 2026, covering nine advanced pharmaceutical products addressing complex medical conditions including rare genetic disorders, hereditary angioedema, hemophilia, and immune disorders. This delivery order represents a routine procurement under that established BPA framework, enabling rapid acquisition of TAKHZYRO for veteran populations without requiring individual competitive procurements.
Quick answers
Who was awarded contract 36C24526N0303?
36C24526N0303 was awarded to Takeda Pharmaceuticals America, Inc. by Veterans Integrated Service Network 5 (Veterans Health Administration) on February 5, 2026.
How much is contract 36C24526N0303 worth?
The government has obligated $38,098 on 36C24526N0303.
Is contract 36C24526N0303 an order under another contract?
Yes. 36C24526N0303 is a delivery order under V797D50492, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36C24526N0303 competed?
The extent of competition for 36C24526N0303 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award